<DOC>
	<DOCNO>NCT00385671</DOCNO>
	<brief_summary>To test non-inferiority duloxetine monotherapy treatment management diabetic peripheral neuropathic pain compare pregabalin treatment among patient adequate response gabapentin .</brief_summary>
	<brief_title>An Open-Label Comparison Duloxetine Other Alternatives Management Diabetic Peripheral Neuropathic Pain</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>You must diagnose Diabetic Neuropathic Pain Patient average daily pain score great equal 4 11point Likert scale , patient provider feel change current gabapentin therapy pain management warrant Patient currently treat gabapentin great equal 900 milligram/day , prescribe current dose least 4 week , least 80 % compliant dosing , accord patient report Patient must agree change dose gabapentin Visits 1 2 You must stable glycemic control Are judge prior randomization suicidal risk define score 2 great question 9 Beck Depression InventoryII ( BDIII ) Current diagnosis history hemangiosarcoma Patients New York Heart Association Class III IV symptom congestive heart failure Patients uncontrolled narrowangle glaucoma Presence current seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>